Drugs for the Treatment of Pediatric Type 2 Diabetes Mellitus and Related Co-Morbidities Publisher Pubmed



Tabatabaeimalazy O^{1, 2} ; Nikfar S^{2, 3} ; Larijani B² ; Abdollahi M^{2, 4, 5} Show Affiliations
Source: Expert Opinion on Pharmacotherapy Published:2016

Abstract

Introduction: The continuing global epidemic of obesity in adolescents has raised the prevalence of type 2 diabetes mellitus (T2DM). Despite the wealth of information concerning T2DM in adults, rare data are available targeting treatment of T2DM in pediatric. Areas covered: This article has reviewed clinical practice guidelines, particularly the American Diabetes Association and the Pediatric Endocrine Society consensus, jointly with clinical trial data available in databases with respect to the use of available pharmacological options to treat T2DM and its complications in youth. Expert opinion: The use of other pharmacological treatments of T2DM in addition to metformin and insulin entails several problems. Since rare studies have been conducted on the medications available to manage T2DM in children, treating them may be more difficult than that of adults. It needs longer and larger size clinical trials along with better pharmacological agents to affect various pathophysiological mechanisms of diabetes. Meanwhile, the efficacy and safety of combinations therapies should be completed in preclinical and clinical phases. © 2016 Informa UK Limited, trading as Taylor & Francis Group.